Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Solid lipid nanoparticles (SLNs) are essentially composed of triglyceride(s) that orient to form a polar core with polar heads oriented toward the aqueous phase, resembling chylomicrons. The composition of such SLNs may alter the course of drug absorption predominantly to and through lymphatic route and regions, presumably following a transcellular path of lipid absorption, especially by enterocytes and polar epithelial cells of the intestine. SLNs were prepared using stearic acid, glycerol monostearate, tristearin, and Compritol 888 ATO by solvent diffusion method using demineralized double-distilled water as the dispersion medium. The SLNs were characterized for shape, size, zeta potential, and percentage drug content and its release. The characterization of SLNs suggests that Compritol 888 ATO-based nanoparticles were heterogeneous with better drug-loading and release characteristics as compared with the other formulations. The selected products were studied for in vivo absorption and hence bioavailability by measure of area under the blood plasma curve plotted as a function of time. Periodic lymphatic concentration of drug following oral administration of respective formulations was also determined by mesenteric duct cannulation and collection of samples. The comparative study conducted on methotrexate (MTX)-bearing SLNs revealed that the formulation based on Compritol 888 ATO could noticeably improve the oral bioavailability of MTX, presumably following SLNs constituting lipid digestion and co-absorption through lymphatic transport and route.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physiology of the Gastrointestinal Tract
(2006) · Elsevier eBooks · doi:10.1016/b978-0-12-088394-3.x5000-4 · Cited by 4,597
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759
Lipid-based vehicles for the oral delivery of poorly water soluble drugs
Humberstone, A. J., & Charman, W. N. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00494-2 · Cited by 577
Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles
Venkateswarlu, V., & Manjunath, K. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.01.005 · Cited by 558
Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique
Trotta, M., Debernardi, F., & Caputo, O. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00135-2 · Cited by 439
Physiology of the Gastrointestinal Tract
(2018) · Elsevier eBooks · doi:10.1016/c2015-1-04889-x · Cited by 338
Intestinal lymphatic drug transport: an update
Porter, C. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00151-x · Cited by 337
Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration
Yang, S., Zhu, J., Lu, Y., Liang, B., & Yang, C. (1999) · Pharmaceutical Research · doi:10.1023/a:1018888927852 · Cited by 324
Fundarò, A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., & Gasco, M. R. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0695 · Cited by 317
Caliph, S. M., Charman, W. N., & Porter, C. J. H. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200008)89:8<1073::aid-jps12>3.0.co;2-v · Cited by 292
Cited by
Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery
Das, S., & Chaudhury, A. (2011) · AAPS PharmSciTech · doi:10.1208/s12249-010-9563-0 · Cited by 838
A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems
Duan, Y., Dhar, A., Patel, C., Khimani, M., Neogi, S., Sharma, P., Siva Kumar, N., & Vekariya, R. L. (2020) · RSC Advances · doi:10.1039/d0ra03491f · Cited by 614
Nanostructured lipid carriers system: Recent advances in drug delivery
Iqbal, M. A., Md, S., Sahni, J. K., Baboota, S., Dang, S., & Ali, J. (2012) · Journal of Drug Targeting · doi:10.3109/1061186x.2012.716845 · Cited by 436
Ganesan, P., & Narayanasamy, D. (2017) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2017.07.002 · Cited by 434
Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
Edis, Z., Wang, J., Waqas, M. K., Ijaz, M., & Ijaz, M. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s289443 · Cited by 390
Duong, V.-A., Nguyen, T.-T.-L., & Maeng, H.-J. (2020) · Molecules · doi:10.3390/molecules25204781 · Cited by 338
Solid lipid nanoparticles: a review on recent perspectives and patents
Paliwal, R., Paliwal, S. R., Kenwat, R., Kurmi, B. D., & Sahu, M. K. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1720649 · Cited by 337
Self-citationAdvanced drug delivery to the lymphatic system: lipid-based nanoformulations
Darwis, Y., Ali Khan, A., Mudassir, J., & Mohtar, N. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s41521 · Cited by 333
Luo, Y., Teng, Z., Li, Y., & Wang, Q. (2015) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2014.12.084 · Cited by 332
Zhuang, C.-Y., Li, N., Wang, M., Zhang, X.-N., Pan, W.-S., Peng, J.-J., Pan, Y.-S., & Tang, X. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.05.005 · Cited by 318
Solid lipid nanoparticles: an oral bioavailability enhancer vehicle
Harde, H., Das, M., & Jain, S. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.604311 · Cited by 281
Lipid-Based Nanoparticles for Drug Delivery Systems
Samimi, S., Maghsoudnia, N., Eftekhari, R. B., & Dorkoosh, F. (2019) · Characterization and Biology of Nanomaterials for Drug Delivery · doi:10.1016/b978-0-12-814031-4.00003-9 · Cited by 266
Tiwari, R., & Pathak, K. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.044 · Cited by 261
Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting
Aji Alex, M. R., Chacko, A. J., Jose, S., & Souto, E. B. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.10.002 · Cited by 258
Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles
Cai, S., Yang, Q., Bagby, T. R., & Forrest, M. L. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.05.017 · Cited by 252
Pardeshi, C. V., Rajput, P. V., Belgamwar, V. S., Tekade, A. R., & Surana, S. J. (2013) · Drug Delivery · doi:10.3109/10717544.2012.752421 · Cited by 141
Tsai, M.-J., Huang, Y.-B., Wu, P.-C., Fu, Y.-S., Kao, Y.-R., Fang, J.-Y., & Tsai, Y.-H. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22285 · Cited by 137
Singh, H., Jindal, S., Singh, M., Sharma, G., & Kaur, I. P. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.02.050 · Cited by 61
Metadata
- Authors
- Paliwal, R., Rai, S., Vaidya, B., Khatri, K., Goyal, A. K., Mishra, N., Mehta, A., & Vyas, S. P.
- Venue
- Nanomedicine: Nanotechnology, Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 5
- Issue
- 2
- Pages
- 184-191
- ISSN
- 1549-9634 (ISSN-L)
- OpenAlex
- W2054727211
- Cited by
- 288
- References
- 26
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.